title: Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
abstract: An in vitro angiotensin II (AngII) receptor-binding assay was developed to monitor the degree of receptor blockade in standardized conditions. This in vitro method was validated by comparing its results with those obtained in vivo with the injection of exogenous AngII and the measurement of the AngII-induced changes in systolic blood pressure. For this purpose, 12 normotensive subjects were enrolled in a double-blind, four-way cross-over study comparing the AngII receptor blockade induced by a single oral dose of losartan (50 mg), valsartan (80 mg), irbesartan (150 mg), and placebo. A significant linear relationship between the two methods was found (r = 0.723, n = 191, P<.001). However, there exists a wide scatter of the in vivo data in the absence of active AngII receptor blockade. Thus, the relationship between the two methods is markedly improved (r = 0.87, n = 47, P<.001) when only measurements done 4 h after administration of the drugs are considered (maximal antagonist activity observed in vivo) suggesting that the two methods are equally effective in assessing the degree of AT-1 receptor blockade, but with a greatly reduced variability in the in vitro assay. In addition, the pharmacokinetic/pharmacodynamic analysis performed with the three antagonists suggest that the AT-1 receptor-binding assay works as a bioassay that integrates the antagonistic property of all active drug components of the plasma. This standardized in vitro-binding assay represents a simple, reproducible, and precise tool to characterize the pharmacodynamic profile of AngII receptor antagonists in humans.
authors.affiliation: Division of Hypertension and Vascular Medicine, University Hospital, Lausanne, Switzerland. Marc.Maillard@chuv.hospvd.ch
authors.forename: M P
authors.initials: MP
authors.lastname: Maillard
authors.forename: L
authors.initials: L
authors.lastname: Mazzolai
authors.forename: V
authors.initials: V
authors.lastname: Daven
authors.forename: C
authors.initials: C
authors.lastname: Centeno
authors.forename: J
authors.initials: J
authors.lastname: Nussberger
authors.forename: H R
authors.initials: HR
authors.lastname: Brunner
authors.forename: M
authors.initials: M
authors.lastname: Burnier
mesh_terms: D000804:Angiotensin II; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D000077405:Irbesartan; D019808:Losartan / Q000494:pharmacology*; D011869:Radioligand Assay; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D015203:Reproducibility of Results; D013777:Tetrazoles / Q000494:pharmacology*; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan; D014662:Vasoconstrictor Agents
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D015415:Biomarkers; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D000068756:Valsartan; D014633:Valine; D000077405:Irbesartan; D019808:Losartan